Drug discovery beyond the 'rule-of-five'

Current Opinion in Biotechnology

Volumn 18, Issue 6, 2007, Pages 478-488

  Zhang, Ming Qiang ^a   Wilkinson, Barrie ^a  

^a BIOTICA TECHNOLOGY LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DISCOVERY; LIVING ORGANISMS; PROTEASES;

BIOACTIVITY; BIOSYNTHESIS; GENETIC ENGINEERING; LIGANDS; MOLECULAR DYNAMICS;

DRUG PRODUCTS;

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; ARGATROBAN; BC 287; BORRELIDIN; CETUXIMAB; ENFUVIRTIDE; ERLOTINIB; FONDAPARINUX; GEFITINIB; HEPARIN; HIRULOG; LAPATINIB; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MACBECIN I; MONOCLONAL ANTIBODY; NATURAL PRODUCT; OBATOCLAX; PENICILLIN G; PENICILLIN V; POLYKETIDE; PROTEIN BCL 2; PROTEIN INHIBITOR; RAPAMYCIN; TANESPIMYCIN; THROMBIN INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIMELAGATRAN;

BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CELL STRAIN CACO 2; CLAISEN CONDENSATION; COMBINATORIAL CHEMISTRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION; LIVER MICROSOME; NEOPLASM; NONHUMAN; NUDE MOUSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PRODUCTIVITY; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; SUPPORT VECTOR MACHINE;

DRUG DESIGN; DRUG INDUSTRY; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 37549071045     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2007.10.005     Document Type: Review

References (40)

1. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23 (1997) 3-25. A seminal paper in which it was proposed that poor absorption or permeability of a compound is more likely when there are >5 hydrogen-bond donors, the molecular mass is >500, clog P is >5, and the sum of nitrogen and oxygen atoms in a molecule is greater than 10. Natural products and drugs that are substrates of biological transporters are exceptions to the rule.
2. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46 (2001) 3-26. A seminal paper in which it was proposed that poor absorption or permeability of a compound is more likely when there are >5 hydrogen-bond donors, the molecular mass is >500, clog P is >5, and the sum of nitrogen and oxygen atoms in a molecule is greater than 10. Natural products and drugs that are substrates of biological transporters are exceptions to the rule.
3. Kubinyi H. Drug research: myths, hype and reality. Nat Rev Drug Discov 2 (2003) 665-668
4. Overington J.P., Al-Lazikani B., and Hopkins A.L. How many drug targets are there?. Nat Rev Drug Discov 5 (2006) 993-996
5. Quan M.L., and Smallheer J.M. The race to an orally active Factor Xa inhibitor: recent advances. Curr Opin Drug Discov Dev 7 (2004) 460-469
6. Schwienhorst A. Direct thrombin inhibitors - a survey of recent developments. Cell Mol Life Sci 63 (2006) 2773-2791
7. Frantz S. Pharma faces major challenges after a year of failures and heated battles. Nat Rev Drug Discov 6 (2007) 5-7
8. Jiang S., Lin K., Strick N., and Neurath A.R. HIV-1 inhibition by a peptide. Nature 365 (1993) 113
9. Poveda E., Briz V., and Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 7 (2005) 139-147
10. Debnath A.K. Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1. Expert Opin Investig Drugs 15 (2006) 465-478
11. Hajduk P.J., and Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6 (2007) 211-219. This paper reviews the development and utilities of this emerging technology with concrete examples on how it is contributing to drug discovery in the pharma/biotech industry. The combination of broader sampling of chemical space and increased hit rates compared to early combinatorial chemistry and high-throughput screening makes it a powerful tool for hit/lead identification.
12. Bruncko M., Oost T.K., Belli B.A., Ding H., Joseph M.K., Kunzer A., Martineau D., McClellan W.J., Mitten M., Ng S.H., et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem 50 (2007) 641-662
13. Fonseca R., and Stewart A.K. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther 6 (2007) 802-810
14. Zhang H., Chen J., Chen Z., Jin S., Nimmer P., Tahir S., Smith M., Xiao Y., Rosenberg S.H., Elmore S.W., and Tse C. The Bcl-2 family protein inhibitor, ABT-263, broadly potentiates the cytotoxicity of other therapeutic agents in vitro. American Association for Cancer Research Annual Meeting Proceedings: 2007 April 14-18; Philadelphia (PA) [abstract nr 726] (2007)
15. Pavlou A.K., and Belsey M.J. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 59 (2005) 389-396
16. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 312 (2006) 1175-1178
17. Newman D.J., and Cragg G.M. Natural products as sources of new drugs over the last 25 years. J Nat Prod 70 (2007) 461-477. This latest review together with the previous two by the same authors (cited in the paper) presents a comprehensive analysis on the impact of natural products to drug discovery. This includes not only the naturally occurring compounds and their direct semisynthetic derivatives but also synthetic drugs that are mimetics of natural products or inspired by natural products.
18. Koch M.A., Schuffenhauer A., Scheck M., Wetzel S., Casaulta M., Odermatt A., Ertl P., and Waldmann H. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proc Natl Acad Sci U S A 102 (2005) 17272-17277. An interesting example of how synthetic chemistry can be employed to biologically relevant or validated structural scaffolds - the so-called biology oriented synthesis (BIOS).
19. Grabowski K., and Schneider G. Properties and architecture of drugs and natural products revisited. Curr Chem Biol 1 (2007) 115-127
20. Charette B.D., MacDonald R.G., Wetzel S., Berkowitz D.B., and Waldmann H. Protein structure similarity clustering: dynamic treatment of PDB structures facilitates clustering. Angew Chem Int Ed 45 (2006) 7766-7770
21. Paterson I., and Anderson E.A. The renaissance of natural products as drug candidates. Science 310 (2005) 451-453
22. Benner S.A., and Sismour A.M. Synthetic biology. Nat Rev Genet 6 (2005) 533-543
23. Van Lanen S.G., and Shen B. Progress in combinatorial biosynthesis for drug discovery. Drug Discov Today Technol 3 (2006) 285-292
24. Staunton J., and Weissman K.J. Polyketide biosynthesis: a millennium review. Nat Prod Rep 18 (2001) 380-416
25. Moss S.J., Martin C.J., and Wilkinson B. Loss of co-linearity by modular polyketide synthases: a mechanism for the evolution of structural diversity. Nat Prod Rep 21 (2004) 575-593
26. Rubio-Viqueira B., and Hidalgo M. Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 7 (2006) 501-512
27. Nakata T. Total synthesis of macrolides. In: Omura S. (Ed). Macrolide Antibiotics: Chemistry, Biology and Practice (2002), Academic Press 220-232
28. Schwecke T., Aparicio J.F., Molnár I., König A., Khaw L.E., Haydock S.F., Oliynyk M., Caffrey P., Cortés J., Lester J.B., et al. The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc Natl Acad Sci U S A 92 (1995) 7839-7843
29. Gregory M.A., Gaisser S., Lill R.E., Hong H., Sheridan R.M., Wilkinson B., Petkovic H., Weston A.J., Carletti I., Lee H.L., et al. Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus. Angew Chem Int Ed Engl 43 (2004) 2551-2553
30. Gregory M.A., Hong H., Lill R.E., Gaisser S., Petkovic H., Low L., Sheehan L.S., Carletti I., Ready S.J., Ward M.J., et al. Rapamycin biosynthesis: elucidation of gene product function. Org Biomol Chem 4 (2006) 3565-3568
31. Gregory M.A., Petkovic H., Lill R.E., Moss S.J., Wilkinson B., Gaisser S., Leadlay P.F., and Sheridan R.M. Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis. Angew Chem Int Ed Engl 44 (2005) 4757-4760. A good example of how genetically engineered biosynthesis can be used effectively to make analogs of a structurally complex natural product lead.
32. Sheridan R.M., Gregory M.A., Petkovic H., Gaisser S., Lill R.E., Ward M.J., Kaja A.L., Beckman C.H., Challis I.R., Moss S.J., et al. Brain-selective mTOR inhibitors as potential therapeutics for glioblastoma multiforme. American Association for Cancer Research Annual Meeting Proceedings: 2006 April 1-5; Washington, DC [abstract nr 5959] (2006)
33. Zhang MQ, Sheridan RM: 39-Desmethoxyrapamycin, compositions and methods of use thereof. US 7,183,289 B2; 2006.
34. Abad-Zapatero C., and Metz J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10 (2005) 464-469
35. Martin C.J., Gaisser S., Vousden W.A., Sheehan L.J., Foster T., Sheridan R.M., Nur-E-alam M., Coates N., Moss S.J., Beckmann C., et al. Towards 'best-in-class' Hsp90 inhibitors: design, biosynthesis and pre-clinical profiles. American Association for Cancer Research Annual Meeting Proceedings: 2007 April 14-18; Philadelphia (PA) [abstract nr 5724] (2007)
36. Tian Z.Q., Liu Y., Zhang D., Wang Z., Dong S.D., Carreras C.W., Zhou Y., Rastelli G., Santi D.V., and Myles D.C. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem 12 (2004) 5317-5329
37. Wilkinson B., Gregory M.A., Moss S.J., Carletti I., Sheridan R.M., Kaja A., Ward M., Olano C., Mendez C., Salas J.A., et al. Separation of anti-angiogenic and cytotoxic activities of borrelidin by modification at the C17 side chain. Bioorg Med Chem Lett 16 (2006) 5814-5817
38. Reichert J.M., and Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6 (2007) 349-356
39. Owens J. 2006 drug approvals: finding the niche. Nat Rev Drug Discov 6 (2007) 99-101
40. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., and Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34 (2006) D668-D672